GPC Biotech and Agennix Announce Proposed Merger
Pipeline to include novel oncology therapy, talactoferrin, which recently entered Phase 3 clinical testing
20-Feb-2009 -
GPC Biotech AG and Agennix, Incorporated announced that the two oncology-focused biotechnology companies have signed a Business Combination Agreement under which they propose to merge their businesses. In the transaction, GPC Biotech is to be merged onto a new German company, which will hold ...
cancer therapy
diabetic foot ulcers
GPC Biotech
+5